ARA-290 — living evidence map

Summary

ARA 290 (cibinetide) is a non-haematopoietic peptide designed from the structure of erythropoietin that interacts selectively with the innate repair receptor mediating tissue protection. · pmid:25387363

History

In a phase 2 study in type 2 diabetes, 28 days of daily subcutaneous ARA 290 was followed by improvements in HbA1c, lipid profiles and neuropathic symptom scores, with no safety issues identified. · pmid:25387363

In a small randomized pilot study of sarcoidosis with small fibre neuropathy, it improved neuropathy screening scores over four weeks compared with placebo. · pmid:23168581

Identity

PubChem CID 91810664: Cibinetide, C51H84N16O21, 1257.3 g/mol. · pubchem:91810664

CAS registry number 1208243-50-8. · pubchem:91810664

Where the evidence actually sits

Proportion of the 2 claims about ARA-290 standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for ARA-290 yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

1. Approved-label dose · a resolved regulatory document names a labelled dose

   nothing resolved on this rung

2. Studied human doses · resolved human studies at the established tier

   nothing resolved on this rung

3. Observational evidence · resolved human data at the emerging tier: thin, or contested
   • Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. · pmid 23168581 · 2012
   • ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. · pmid 25387363 · 2015
4. Community-reported protocols · protocol propositions from distinct members, counted once per human

   nothing resolved on this rung

5. Preclinical evidence · resolved animal, cell or mechanistic work

   nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.